162 related articles for article (PubMed ID: 24436453)
21. Trial results finally show potential for microbicidal HIV gel.
Mohammadi D
Lancet Infect Dis; 2010 Sep; 10(9):587. PubMed ID: 20815108
[No Abstract] [Full Text] [Related]
22. Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques.
Nuttall J; Kashuba A; Wang R; White N; Allen P; Roberts J; Romano J
Antimicrob Agents Chemother; 2012 Jan; 56(1):103-9. PubMed ID: 21986823
[TBL] [Abstract][Full Text] [Related]
23. Inefficient vaginal transmission of tenofovir-resistant HIV-1.
Chateau M; Swanson MD; Garcia JV
J Virol; 2013 Jan; 87(2):1274-7. PubMed ID: 23115295
[TBL] [Abstract][Full Text] [Related]
24. Tenofovir gel--the new HIV prevention 'banker'?
Bateman C
S Afr Med J; 2007 Jul; 97(7):496, 498. PubMed ID: 17805450
[No Abstract] [Full Text] [Related]
25. Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications.
Krakower D; Mayer KH
Curr HIV/AIDS Rep; 2011 Dec; 8(4):241-8. PubMed ID: 22002729
[TBL] [Abstract][Full Text] [Related]
26. Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course.
Prada N; Davis B; Jean-Pierre P; La Roche M; Duh FM; Carrington M; Poles M; Mehandru S; Mohri H; Markowitz M
J Acquir Immune Defic Syndr; 2008 Oct; 49(2):117-22. PubMed ID: 18769360
[TBL] [Abstract][Full Text] [Related]
27. Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model.
Destache CJ; Mandal S; Yuan Z; Kang G; Date AA; Lu W; Shibata A; Pham R; Bruck P; Rezich M; Zhou Y; Vivekanandan R; Fletcher CV; Li Q
Antimicrob Agents Chemother; 2016 Jun; 60(6):3633-9. PubMed ID: 27044548
[TBL] [Abstract][Full Text] [Related]
28. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.
Denton PW; Othieno F; Martinez-Torres F; Zou W; Krisko JF; Fleming E; Zein S; Powell DA; Wahl A; Kwak YT; Welch BD; Kay MS; Payne DA; Gallay P; Appella E; Estes JD; Lu M; Garcia JV
J Virol; 2011 Aug; 85(15):7582-93. PubMed ID: 21593172
[TBL] [Abstract][Full Text] [Related]
29. Assessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: results of a nested case-control study.
MacQueen KM; Weaver MA; van Loggerenberg F; Succop S; Majola N; Taylor D; Karim QA; Karim SA
AIDS Behav; 2014 May; 18(5):826-32. PubMed ID: 24647763
[TBL] [Abstract][Full Text] [Related]
30. Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models.
van de Vijver DA; Nichols BE; Abbas UL; Boucher CA; Cambiano V; Eaton JW; Glaubius R; Lythgoe K; Mellors J; Phillips A; Sigaloff KC; Hallett TB
AIDS; 2013 Nov; 27(18):2943-51. PubMed ID: 23939237
[TBL] [Abstract][Full Text] [Related]
31. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.
Lehman DA; Baeten JM; McCoy CO; Weis JF; Peterson D; Mbara G; Donnell D; Thomas KK; Hendrix CW; Marzinke MA; Frenkel L; Ndase P; Mugo NR; Celum C; Overbaugh J; Matsen FA;
J Infect Dis; 2015 Apr; 211(8):1211-8. PubMed ID: 25587020
[TBL] [Abstract][Full Text] [Related]
32. A second chance for microbicides.
Baleta A
Lancet; 2007 Jul; 370(9581):17-8. PubMed ID: 17632853
[No Abstract] [Full Text] [Related]
33. Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women.
Fisher KL; Mabuka JM; Sivro A; Ngcapu S; Passmore JS; Osman F; Ndlovu B; Abdool Karim Q; Abdool Karim SS; Chung AW; Baxter C; Archary D
Front Immunol; 2020; 11():1274. PubMed ID: 32733445
[TBL] [Abstract][Full Text] [Related]
34. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.
Liegler T; Abdel-Mohsen M; Bentley LG; Atchison R; Schmidt T; Javier J; Mehrotra M; Eden C; Glidden DV; McMahan V; Anderson PL; Li P; Wong JK; Buchbinder S; Guanira JV; Grant RM;
J Infect Dis; 2014 Oct; 210(8):1217-27. PubMed ID: 24740633
[TBL] [Abstract][Full Text] [Related]
35. Importance of early identification of PrEP breakthrough infections in a generalized HIV epidemic: a case report from a PrEP demonstration project in South Africa.
Naicker CL; Mansoor LE; Dawood H; Naidoo K; Singo D; Matten D; Williamson C; Abdool Karim Q
BMC Infect Dis; 2020 Jul; 20(1):532. PubMed ID: 32698772
[TBL] [Abstract][Full Text] [Related]
36. The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment.
Seay K; Khajoueinejad N; Zheng JH; Kiser P; Ochsenbauer C; Kappes JC; Herold B; Goldstein H
J Virol; 2015 Sep; 89(18):9559-70. PubMed ID: 26157126
[TBL] [Abstract][Full Text] [Related]
37. Vaginal deployment and tenofovir delivery by microbicide gels.
Gao Y; Yuan A; Chuchuen O; Ham A; Yang KH; Katz DF
Drug Deliv Transl Res; 2015 Jun; 5(3):279-94. PubMed ID: 25874971
[TBL] [Abstract][Full Text] [Related]
38. High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.
Skhosana L; Steegen K; Bronze M; Lukhwareni A; Letsoalo E; Papathanasopoulos MA; Carmona SC; Stevens WS
PLoS One; 2015; 10(2):e0118145. PubMed ID: 25659108
[TBL] [Abstract][Full Text] [Related]
39. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
Minnis AM; Gandham S; Richardson BA; Guddera V; Chen BA; Salata R; Nakabiito C; Hoesley C; Justman J; Soto-Torres L; Patterson K; Gomez K; Hendrix CW
AIDS Behav; 2013 Feb; 17(2):737-47. PubMed ID: 23065145
[TBL] [Abstract][Full Text] [Related]
40. Impact of Tenofovir gel as a PrEP on HIV infection: a mathematical model.
Rahman SM; Vaidya NK; Zou X
J Theor Biol; 2014 Apr; 347():151-9. PubMed ID: 24380779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
